Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  ranpirnase
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-7 of 7 for your search:
Start Over
Phase III Randomized Study of Weekly Intravenous P-30 Protein plus Daily Oral TMX vs Weekly Intravenous 5-FU for Advanced Pancreatic Cancer (Summary Last Modified 01/99)
Phase: Phase III
Type: Treatment
Status: Completed
Age: 21 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ALFACELL-P30-300, NCI-V95-0752
Phase III Randomized Study of Weekly Intravenous P-30 Protein plus Daily Oral Tamoxifen vs Weekly Intravenous Gemcitabine for Advanced Pancreatic Cancer (Summary Last Modified 08/98)
Phase: Phase III
Type: Treatment
Status: Closed
Age: 21 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ALFACELL-P30-303, NCI-V96-0938
Phase II Pilot Study of Weekly Intravenous P-30 Protein plus Daily Oral Tamoxifen for Prostate Cancer Patients with an Elevated PSA After Failing Local Therapy (Summary Last Modified 03/98)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 21 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ALFACELL-P30-400, NCI-V96-0937
Phase II Study of P-30 Protein Administered as a Single Weekly Intravenous Bolus Dose in Advanced Malignant Mesothelioma (Summary Last Modified 06/97)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 21 and over
Sponsor: Other
Protocol IDs: TCSC-P-30-P/PHII, NCI-V92-0008
A Study Of Ranpirnase(Onconase®) To Pemetrexed Plus Carboplatin In Patients With Non-Squamous Non-Small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Status: Temporarily closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: P30-800, NCT01184287
Phase I Study of P-30 Protein Administered by Weekly Intravenous Bolus Injections in Patients with Cancer (Summary Last Modified 02/91)
Phase: Phase I
Type: Treatment
Status: Closed
Age: 21 and over
Sponsor:
Protocol IDs: TCSC-P-30-PROTEIN, NCI-V90-0188
Start Over